Literature DB >> 23357592

Sudden sensorineural hearing loss: results of intratympanic steroids as salvage treatment.

Francesco Dispenza1, Alessandro De Stefano, Claudio Costantino, Donatella Marchese, Francesco Riggio.   

Abstract

OBJECTIVE: The aim of the present study was to verify the efficacy and the safety of intratympanic dexamethasone to treat sudden sensorineural hearing loss as salvage therapy.
MATERIALS AND METHODS: A prospective study was conducted on patients affected by idiopathic sudden hearing loss who were treated before with some systemic therapy, but without recovery of the hearing The patients able to undergo the study, but who refused salvage treatment were considered as control group. A solution of Dexamethasone 4 mg/ml was then injected through the posterior-inferior quadrant filling completely the middle ear. The follow-up in the following 6 months included an audiogram every month.
RESULTS: The number of patients treated with salvage therapy was 36. The patients who refused treatment were further 10. The salvage treatment was done with a mean delay of 24.3 days from the onset of symptoms. Mean hearing threshold after the onset of sudden hearing loss at PTA was 66.5 dB. After the failed treatment the mean PTA was 59.6 dB. The mean PTA after the intratympanic steroid administration was 46.8 dB, with a mean improvement of 12.8 dB. No hearing change was noted in the 10 patients who refused salvage therapy. The patients that assumed systemic steroid as first therapy showed a better PTA threshold after the salvage intratympanic treatment (p<0.01). A significant difference (p<0.05) of hearing recovery was evidenced between non-smoker patients and those with smoking habit.
CONCLUSIONS: Our data showed that a salvage treatment with intratympanic dexamethasone should be suggested to all patients who failed the first systemic treatment. The systemic steroid therapy done before the salvage treatment seems to exert a protective role for the inner ear, as shown by our series. On the contrary the smoke habit is a negative prognostic factor in the hearing recovery.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23357592     DOI: 10.1016/j.amjoto.2012.12.010

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  7 in total

1.  Hearing Changes After Intratympanic Steroids for Secondary (Salvage) Therapy of Sudden Hearing Loss: A Meta-Analysis Using Mathematical Simulations of Drug Delivery Protocols.

Authors:  Arne Liebau; Olivia Pogorzelski; Alec N Salt; Stefan K Plontke
Journal:  Otol Neurotol       Date:  2018-08       Impact factor: 2.311

2.  Oral steroid treatment for idiopathic sudden sensorineural hearing loss.

Authors:  Wei T Chen; Jui W Lee; Chien H Yuan; Rong F Chen
Journal:  Saudi Med J       Date:  2015-03       Impact factor: 1.484

Review 3.  Auditory disorders and future therapies with delivery systems.

Authors:  Jung-Hwan Lee; Min Young Lee; Yohan Lim; Jonathan Knowles; Hae-Won Kim
Journal:  J Tissue Eng       Date:  2018-10-30       Impact factor: 7.813

4.  Optimal timing of salvage intratympanic steroids in idiopathic sudden sensorineural hearing loss.

Authors:  Yongzhen Wu; Zijun Song; Yi Wang; Hui Zhao; Tongli Ren; Jianghua Jing; Na Gao; Liang Qiao; Jing Wang
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-09-14

5.  Clinical Analysis of Intratympanic Injection of Dexamethasone for Treating Sudden Deafness.

Authors:  Xin Li; Wen-Jing Chen; Jia Xu; Hai-Jin Yi; Jing-Ying Ye
Journal:  Int J Gen Med       Date:  2021-06-16

Review 6.  An overview of pharmacology and clinical aspects concerning the therapy of cochleo-vestibular syndromes by intratympanic drug delivery.

Authors:  Felician Chirteş; Silviu Albu
Journal:  Clujul Med       Date:  2013-08-05

7.  Addition of intratympanic steroid or hyperbaric oxygen treatment to systemic steroid treatment in sudden idiopathic sensorineural hearing loss treatment, and long-term results of salvage treatment

Authors:  Kemal Keseroğlu; Gökhan Toptaş; Ahmet Uluat; Ömer Bayir; Emel Çadalli Tatar; Güleser Saylam; Mehmet Hakan Korkmaz; Ali Özdek
Journal:  Turk J Med Sci       Date:  2020-02-13       Impact factor: 0.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.